Biotech China 2014

View Profile

Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2012 Intracerebral CpG Immunotherapy with Carbon Nanotubes Abrogates Growth of Subcutaneous Melanomas in Mice. Clin.Cancer Res., 18(20):5628-5638, 2012. PM:22904105
2. 2012 A Vaccine Based on the Rhesus Cytomegalovirus UL128 Complex Induces Broadly Neutralizing Antibodies in Rhesus Macaques J. Virol, 10/2012. doi: 10.1128/JVI.01669-12
3. 2012 Patterns of Acute Rhesus Cytomegalovirus (RhCMV) Infection Predict Long-Term RhCMV Infection. J. of Virology, 86: 6354-6357,2012. PM:22491451
4. 2012 Clinical Evaluation of Safety and Immunogenicity of PADRE-CMV and Tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant Journal of Infectious Diseases, 205:1294-1304, 2012
5. 2012 A road less traveled paved by IDO silencing: Harnessing neutrophils for anti-tumor activity In Press, OncoImmunology, 12/2012
6. 2012 Systemic Delivery of Salmonella Typhimurium Transformed with IDO shRNA Enhances Intratumoral Vector Colonization and Suppresses Tumor Growth Cancer Research, 72:6447-6456, 2012. PM:23090116
7. 2012 The immune response to human cytomegalovirus Future Virology, 7(3): 279-293, 2012.
8. 2012 Survivin the Battle Against Immunosuppression: Author’s View OncoImmunology, 1(2): 240-241, 2012
9. 2011 CD154 expression correlates with neutralizing antibody titer against Influenza post- vaccination in stem cell transplant patients and healthy adults. BBMT, 17(4):524-533, 2011. PM:20457264
10. 2011 Vaccine-Induced Control of Viral Shedding following Rhesus Cytomegalovirus Challenge in Rhesus Macaques. J. Virology, 85(6):2878-2890, 2011. PM: 21191005
11. 2011 Recombinant Modified Vaccinia Virus Ankara (MVA) Expressing Wild Type Human p53 Induces Specific Anti-tumor CTL Expansion. Cancer Investigation, 29:501-510 2011. PM:21843052
12. 2011 Open reading frames carried on UL/b' are implicated in shedding and horizontal transmission of rhesus cytomegalovirus in rhesus monkeys J Virol. (10):5105-14, 2011
13. 2011 Primary response against CMV during antiviral prophylaxis with valganciclovir in solid organ transplant recipients Transplant International, 24(9):920-931, 2011. PM:21672050
14. 2011 Characterization of immunological properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice. Blood, 118(8):2159-2169, 2011. PMID: 21719601
15. 2011 Enhancement of Cancer Vaccine Therapy by Systemic Delivery of a Tumor Targeting Salmonella-based STAT3 shRNA Suppresses the Growth of Established Melanoma Tumors Cancer Research, 71:4183-4191, 2011. PM: 21527558
16. 2011 Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity Clinical Cancer Research. 17 (4):771-782, 2011. PM: 21088258
17. 2011 Modified vaccinia Ankara (MVA) expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. Cancer Immunology & Immunotherapy, 60(1):99 -109, 2011. PM: 20960189
18. 2010 PD-1 and IL-10 in liver transplant recipients at high risk for late cytomegalovirus disease Transplant Infectious Disease. 12(4):363-70, 2010. PM:20070620
19. 2010 Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression JIT, 33(6):609-617, 2010. PM:20551836
20. 2010 Intergenic region 3 of MVA is a stable site for insert gene expression and facilitates potent antigen-specific immune responses Virology, 403(2):155-162, 2010. PM:20471051
21. 2010 Predictors of reported influenza vaccination in HIV-infected women in the United States Preventive Medicine, 50(5-6):223-2299, 2010. PM:20303362
22. 2010 Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines Vaccine, 28(6):1547-1557, 2010. PM:19969118
23. 2009 Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood 113 (25):6465-6476, 2009. PM:19369230
24. 2009 Increased programmed death-1 molecule expression in CMV disease and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. BBMT, 15(7):872-880, 2009. PM:19539220
25. 2009 The effect of single and combined activating KIR genotypes on CMV infection and immunity after hematopoietic cell transplant BBMT, 15:315-325, 2009. PM:19203722
26. 2009 Mamu-A01/K(b) transgenic and MHC Class I knockout mice as a tool for HIV vaccine development Virology, 387(1):16-28, 2009. PM:19249807
27. 2008 PD-1 expression in liver transplant recipients as a prognostic indicator of CMV disease J Infect.Dis. 197 (1):25-33, 2008. PM:18171281
28. 2008 A novel approach to evaluate the immunogenicity of viral antigens of clinical importance in HLA transgenic murine models Immunology Letters, 120:108-116, 2008. PM:18706443
29. 2008 A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector Virology, 377(2): 379-390, 2008. PM:18538366
30. 2008 Evaluation of recombinant modified vaccinia Ankara virus-based rhesus CMV in rhesus macaques MMI, 197(2):117-123, 2008. PM:18196272
31. 2007 Longitudinal assessment of CMV-specific immune responses in liver transplant recipients at high risk for late CMV disease J. of Infectious Diseases, 195:633-644, 2007. Editorial Commentary by Boeckh and Riddell in same issue (195:615-617).
32. 2007 Functional characterization of BK virus-specific cytotoxic CD4+ T-cells in seropositive healthy adults Viral immunology, 20(3):379-388, 2007. PM:17931108
33. 2007 Oblimersen and α-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium J. Cancer Res. Clin. Oncol., 133(10):705-711, 2007. PM: 17508219
34. 2007 An MVA vaccine overcomes tolerance to human p53 in mouse and humans Cancer Immunology & Immunotherapy, 56(8): 1193-1205, 2007
35. 2006 Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection J. of Clinical Virology, 35(3):324-331, 2006. PM:16388983
36. 2006 Vaccine Properties of a Novel Marker Gene-Free Recombinant Modified Vaccinia Ankara (MVA) Expressing Immunodominant CMV Antigens pp65 and IE1. Vaccine, 25(6):1132-1141, 2006. PM:17049414
37. 2006 Functional Comparison of T-Cells Recognizing CMV pp65 and IE1 Polypeptides in HSCT and SOT Recipients. J. of Infectious Diseases 194: 1410-1421, 2006. PM:17054071
38. 2006 Cross-reactive CTL recognizing two HLA-A*02-restricted epitopes within the BK virus and JC virus VP1 polypeptides are frequent in immunocompetent individuals Virology 350 (1):128-136, 2006. PM:16600320
39. 2006 In Vitro Expansion of Polyclonal T cells Subsets for Adoptive Immunotherapy by Recombinant Modified Vaccinia Ankara Experimental Hematology, 34(4):497-507, 2006. PM:16569596
40. 2006 Human cytomegalovirus vaccine: Time to look for alternative options. Trends in Molecular Medicine, 12(1):26-33, 2006. PM:16337831
41. 2005 Maria M. and Diamond DJ. Characterization of Host Immunity to CMV-pp150 (UL32). Human Immunology, 66 (2):115-125, 2005.
42. 2005 CMV Immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplantation irrespective of detectable CMV infection. BBMT, 11(11):890-902, 2005. PM:16275592
43. 2005 Cross reactivity of T-lymphocytes recognizing a human cellular epitope within BK and JC virus VP1 polypeptides J.of Virology, 79 (17):11170-11178, 2005.
44. 2005 Lack of association of CMV with human brain tumors. Modern Pathology, 18: 838-843, 2005
45. 2005 Reduced type 1 and type 2 cytokines in anti-viral memory T helper function among women co-infected with HIV and HCV J. Clinical Immunology, 25(2):134-41, 2005. PM:15821890
46. 2005 Novel Conjugates of Epitope Fusion Peptides with CpG-ODN Display Enhanced Immunogenicity and HIV Recognition. Vaccine, 23(26): 3453-68, 2005
47. 2005 Simultaneous Reconstitution of Multiple CMV-Specific CD8+ T–cell Populations with Divergent Functionality In Hematopoietic Stem Cell Transplant Recipients J. of Infectious Disease, 191 (6):977-84, 2005. PM:15717275
48. 2004 Attenuated Poxviruses Generate Clinically Relevant Frequencies of CMV-Specific T cells Blood, 104(3):847-856, 2004. PM:15090456
49. 2004 Human Cytomegalovirus Proteins pp65 and IE1 are Common Targets for CD8+ T cell Responses in Children with Congenital or Postnatal Human CMV infection. J. Immunol., 172(4): 2256-2264, 2004
50. 2004 Predominant type 1 CMV-Specific memory T-helper response in humans: evidence for gender differences in cytokine secretion. Hum.Immunol. 65 (5):476-485, 2004
51. 2004 Recombinant MVA expressing a soluble form of Glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of CMV J. of Virology, 78(8): 3965-3976, 2004. PM:15047812
52. 2004 Assessment of Cellular Immunity to Human Cytomegalovirus in Recipients of Allogeneic Stem Cell Transplants BBMT, 10(7):433-447, 2004. PM:15205665
53. 2004 Two Distinct Pathways of Immuno-modulation Improve Potency of p53 Immunization in Rejecting Established Tumors Cancer Research, 64 (15):5407-5414, 2004. PM:15289349
54. 2004 DNA and low titer, helper-free, recombinant AAV for CMV prime boost vaccination induces an immune response to CMV-pp65 and CMV-IE1 in transgenic HLA A*0201 mice Vaccine, 23 (6):819-826, 2004. PM:15542207
55. 2003 Immunization with TH-CTL Fusion Peptide and CpG DNA in Transgenic HLA A2 Mice Induces Recognition of HIV-infected T cells and Clears a Vaccinia Virus Challenge. J. Immunol. 171(8): 4028-39, 2003
56. 2003 Relevance of Peptide Avidity to the TCR for CMV-specific ex vivo CD8 T Cell Cytotoxicity. J. of Inf. Disease, 188(6): 908-918, 2003. PM:12964124
57. 2003 Relative dominance of HLA-B*07-Restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles Human Immunology 64: 440-452, 2003
58. 2003 CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in a established murine tumor model J. Immunol. 170: 3401-3407, 2003
59. 2002 Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology 106:113-121, 2002.
60. 2002 Kinase-deficient CMVpp65 triggers a CMVpp65-specific T-cell immune response in HLA-A*0201 transgenic mice after DNA immunization Scan. Journal of Immunology 55: 592-598, 2002.
61. 2002 A Functional Recombinant Single-Chain T Cell Receptor Fragment Capable of Selectively Targeting Antigen-Presenting Cells. Cancer Immunol Immunother 51: 565-573, 2002.
62. 2002 Pre-clinical Development of an Adjuvant-Free Peptide Vaccine with Activity Against CMV pp65 in HLA Transgenic Mice. Blood 100(10):3681-3689, 2002.
63. 2002 Characterization of Cytotoxic Function of CMV-pp65-Specific CD8+ T-lymphocytes Identified by HLA Tetramers in Recipients and Donors of Stem Cell Transplants. Transplantation 74 (5):722-732, 2002.
64. 2001 Enhanced Immune Activity of CTL Epitope Analogues Derived from Positional Scanning Synthetic Combinatorial Libraries Blood 97(6):1776-1786, 2001
65. 2001 HIV patients undergoing HAART maintain activated CD8+ cell subsets as a strong adaptive immune response to CMV J. of Infectious Disease 184:256-267,2001
66. 2001 Infrequent Occurrence of Natural Mutations in the pp65 495-503 Epitope Sequence Presented by the HLA A*0201 Allele among Human Cytomegalovirus Isolates J. of Virology 75(5): 2472-2474, 2001
67. 2001 Site-directed mutation in a conserved kinase domain of human cytomegalovirus-pp65 with preservation of cytotoxic T lymphocyte targeting Vaccine 19 (13-14):1628-1635, 2001.
68. 2001 Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes Immunogenetics 52 (3-4):165-173, 2001. PM:11220618
69. 2000 CTL response to human cytomegalovirus minimal epitope vaccination in HLA-A2.1/HLA-DR1 transgenic mice: Dependence of class I MHC-restricted immune response on TH epitope interaction with MHC CLASS II. Human Immunology, 61(8):764-779, 2000.
70. 2000 Status of CMV prevention and treatment in 2000. Hematology 2000, pp 339-356, 2000
71. 2000 Targeting of Human p53- overexpessing Tumor Cells by an HLA A*0201-restricted Murine T-Cell Receptor Expressed in Jurkat T cells Cancer Research, 60:693-701, 2000. PM:10676655
72. 1999 Immunotherapy of bladder cancer by targeting p53 Journal of Urology, 162(5):1806-11, 1999. PM:10524939
73. 1999 An orthotopic in vivo model of human pancreatic cancer Surgery, 126 (3): 562-567, 1999. PM:10486610
74. 1998 An HLA-restricted p53 specific immune response from HLA transgenic p53 knockout mice. Ann. Surg. Oncol. 5(1):93-99, 1998
75. 1998 Targeting p53 for adoptive T Cell immunotherapy McCartyTM, Liu X, Sun J, Peralta EA, Diamond DJ, and Ellenhorn JDI
76. 1997 Targeting p53 for adoptive T cell immunotherapy Owen H. Wangensteen Surgical Forum, 48,783-785, 1997
77. 1997 Development of an Candidate HLA A*0201 restricted peptide-based vaccine against human CMV infection. Blood (Rapid Communication), 90: 1751-1767, 1997.
78. 1997 The use of transgenic mice to generate p53 specific and HLA restricted cytolytic T cells (CTL). Journal of Surgical Research, 69: 337-343, 1997.
79. 1997 Lipid anchored and soluble forms of TCR molecules The Human Antigen T Cell Receptor: Selected Protocols and Applications. Georgetown, TX: R. G. Landes Company 1997, pp 546-631.
80. 1997 Methods for determining expression and oligoclonality of TCRs in GVHD lesions from allogeneic BMT recipients In:Oksenberg, J. R. (ed). The Human Antigen T Cell Receptor: Selected Protocols and Applications. Georgetown, TX: R. G. Landes Company 1997, pp 432- 459.
81. 1996 Generation of p53 specific and HLA restricted cytolytic T lymphocytes using recombinant vaccinia virus and HLA transgenic mice Owen H. Wangensteen Surgical Forum, 47: 503-505
82. 1996 Molecular analysis of T cell receptor repertoire in bone marrow transplant recipients: evidence for oligoclonal T cell expansion in GVHD lesions Blood, 87: 3032-3044
83. 1995 Immunohistochemical analysis of T cell phenotypes in patients with graft versus host disease following allogeneic bone marrow transplantation Transplantation, 59: 1436-1444
84. 1994 Direct binding of Antigen to Lipid anchored and soluble forms of an MHC independent human α/β T cell receptor Molecular Immunology, 31: 857-872
85. 1992 Characterization of nuclear protein binding to the Interferon-γ promoter in quiescent and activated human T cells Eur. J. of Immunol., 22: 2419-2428
86. 1992 Activation and inhibition of human T cell receptor transfectants by defined soluble antigen arrays J. of Expt. Med. 176: 1421-1430 (1992).
87. 1991 The human Interferon-gene contains an inducible promoter that can be transactivated by Tax I and II European J. of Immunology, 21: 1879-1885
88. 1991 MHC independent T cell receptor-antigen interaction: Functional analysis using fluorescein derivatives J.Exp.Med., 174:229-241(1991)
89. 1989 Lineage-Specific Expression of a T-Cell Receptor Variable Gene Promoter Controlled By Upstream Sequences J. of Exp. Med., 169:1213-1231
90. 1988 The gene for T11 (CD2) maps to chromosome 1 in humans and to chromosome 3 in Mice J. of Immunol. 140:361-367
91. 1988 Exon-intron organization and sequence comparison of human and murine T11 (CD2) genes Proc. Natl. Acad. Sci. USA, 85:1615-1619
92. 1985 Regulation of growth hormone mRNA synthesis by dexamethasone and triiodothyronine: Transcriptional rate and mRNA stability changes in pituitary tumor cells J. of Mol. Biol. 181: 41-62 (1985).
93. 1985 Effects of rat growth hormone releasing factor and somatostatin on the release and synthesis of rGH in dispersed pituitarycells. Endocrin, 117: 457-467 (1985)
94. 1985 Unusual organization and diversity of T cell receptor alpha chain genes. Nature (London) 316, 828-830 (1985). PM:2993907
95. 1982 Structure, evolution and expression of mammalian insulin genes Molecular Genetic Neuroscience, pp.103-115. New York: Raven Press (1982)
96. 1982 Disproportionate expression of the two non-allelic rat insulin genes of a pancreatic tumor is due to translational control Cell, 31: 531-542 (1982)
97. 1982 Structure, expression and evolution of growth hormone genes. Rec. Prog. Hor. Res, 38: 198-225 (1982).
98. 1977 RNA molecular weight determination by gel electrophoresis under denaturing conditions: A critical re-examination. Biochemistry, 16: 4743-4750 (1977).
99. 1973 Studies at the scute locus of Drosophila melanogaster Seccan News Magazine, 4: 1-4 (1973)

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.